Title: Incidence and clinical profile of Triple negative breast cancer in Kashmir
Authors: Wani Shahid Bashir, Shah Saqib Ahmad, Lone Mansoor, Sofi Mushtaq Ahmad, Najmi Arshad Manzoor, Teli Mohd. Ashraf, Sheikh Aejaz Aziz, Lone Mohd. Maqbool, Afroz Fir
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.162
Abstract
Introduction
Breast cancer is a heterogenous disease, encompassing a plethora of entities which not only have distinct morphological features but also clinical behaviour. In recent years it has become apparent that this diversity may be underpinned by distinct patterns of genetic, epigenetic and transcriptomic abberations1.
Tiple negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptors as well as human epidermal growth factor receptor-2. It is charecterised by distinct molecular, histological and clinical features including a particularly unfavourable prognosis despite increased sensit-ivity to standard cytotoxic chemotherapy regimes.
The epidemiological risk factors of TNBC compared to non TNBC appear to differ significantly. Overall, the prevalence of TNBC in large unselected breast cancer patient cohorts is 11-20%[2,3], whereas in selected cohorts of patients with advanced breast cancer or patients of African-American ethnicity, TNBC may be diagnosed among as many as 23-28% of all patients[4,5] and in Asian populations upto 25-31%.6
References
1. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, Jong D, Vijver MJ, Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008, 216: 141-150. 10.1002/path.2407.
2. Rakha E, El-Sayed M, Green A et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
3. Cheang MCU, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376.
4. Millikan R, Newman B, Tse C-K et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123.
5. Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-1166.
6. DOI: 10.1200/JGO.2016.005397 Journal of Global Oncology2, no. 6(December 2016) 412-421.
7. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. Cancer 2008; 113: 2638-2645.
8. Andrew A. Davis and Virginia G. Kaklamani, “Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm,” International Journal of Breast Cancer, vol. 2012, Article ID 809291, 10 pages, 2012. doi:10.1155/2012/809291.
9. Kandel MJ, Stadler Z, Masciari S et al. Prevalence of BRCA1 mutations in triple negative breast cancer(BC). J Clin Oncol (Meeting Abstracts) 2006; 24: (Abstr 508).